Home β€Ί Healthcare β€Ί Healthcare IT β€Ί Digital Biomarkers Market

Digital Biomarkers Market Size, Share, Opportunities, And Trends By Type (Mobile Health Apps, Wearable Devices, Others), By Therapeutic Area (Cardiovascular Disorders, Neurological Disorders, Respiratory Disorders, Metabolic Disorders, Others), By End User (Pharmaceutical Companies, Healthcare Providers, Research Organizations, Others), And By Geography - Forecasts From 2025 To 2030

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Table of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL ADVANCEMENTS

5. DIGITAL BIOMARKERS MARKET BY TYPE

5.1. Introduction

5.2. Mobile Health Apps

5.3. Wearable Devices

5.4. Others

6. DIGITAL BIOMARKERS MARKET BY THERAPEUTIC AREA

6.1. Introduction

6.2. Cardiovascular Disorders

6.3. Neurological Disorders

6.4. Respiratory Disorders

6.5. Metabolic Disorders

6.6. Others   

7. DIGITAL BIOMARKERS MARKET BY END-USER

7.1. Introduction

7.2. Pharmaceutical Companies

7.3. Healthcare Providers

7.4. Research Organizations

7.5. Others    

8. DIGITAL BIOMARKERS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type

8.2.2. By Therapeutic Area

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Type

8.3.2. By Therapeutic Area

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Type

8.4.2. By Therapeutic Area

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Type

8.5.2. By Therapeutic Area

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Type

8.6.2. By Therapeutic Area

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Biofourmis Inc. 

10.2. Evidation Health Inc. 

10.3. ResMed Inc. 

10.4. Verily Life Science LLC 

10.5. Empatica Inc. 

10.6. Koneska Health Inc. 

10.7. Biobeat Technologies Ltd. 

10.8. ActiGraph LLC 

10.9. Huma Therapeutics Ltd. 

10.10. Neurometrix Inc. 

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

REPORT DETAILS

Report ID:KSI061615676
Published:Jun 2025
Pages:147
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us